YU85303A - Upotreba enantiomerno čistog escitaloprama - Google Patents
Upotreba enantiomerno čistog escitalopramaInfo
- Publication number
- YU85303A YU85303A YU85303A YUP85303A YU85303A YU 85303 A YU85303 A YU 85303A YU 85303 A YU85303 A YU 85303A YU P85303 A YUP85303 A YU P85303A YU 85303 A YU85303 A YU 85303A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- disorders
- disorder
- treatment
- enantiomeric pure
- medicaments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Sadašnji pronalazak se odnosi na upotrebu enantiomerno čistog escitaloprama i/ili niske doze medikamenata spravljenih od njega za poboljšano lečenje depresije, posebno ozbiljnog poremećaja depresije, živčanih poremećaja, poremećaja akutnog stresa, poremećaja u ishrani kao što su bulimija, anoreksija i gojaznost, fobija, distimija, pred menstrualnog sindroma, kognitivnih poremećaja, poremećaja kontrole impulsa, hiperaktivnog poremećaja nedostatka pažnje ili zloupotrebe lekova. Medikamenti mogu takođe biti upotrebljeni u lečenju ozbiljnog poremećaja depresije kod "na lečenje otpornih" pacijenata.[The present invention relates to the use of enantiomeric pure escitalopram and/or of low dose medicaments thereof for the improved treatment of depression, in particular major depression disorder, neurotic disorders, acute stress disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, pre-menstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder or drug abuse. The medicaments may also be used in the treatment of major depression disorder in "treatment resitant" patients.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200100684 | 2001-05-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
YU85303A true YU85303A (sh) | 2006-05-25 |
Family
ID=8160464
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
YU85303A YU85303A (sh) | 2001-05-01 | 2002-05-01 | Upotreba enantiomerno čistog escitaloprama |
Country Status (25)
Country | Link |
---|---|
US (7) | US20040198809A1 (sh) |
EP (1) | EP1385503A1 (sh) |
JP (1) | JP2004527551A (sh) |
KR (2) | KR20100012089A (sh) |
CN (1) | CN1509169A (sh) |
AR (1) | AR033308A1 (sh) |
AT (1) | AT10974U1 (sh) |
BG (1) | BG108379A (sh) |
BR (1) | BR0208283A (sh) |
CA (1) | CA2445843A1 (sh) |
CZ (1) | CZ20033267A3 (sh) |
EA (1) | EA200301195A1 (sh) |
HR (1) | HRP20030744A2 (sh) |
HU (1) | HUP0400054A3 (sh) |
IL (1) | IL158031A0 (sh) |
IS (1) | IS6954A (sh) |
ME (1) | MEP5908A (sh) |
MX (1) | MXPA03008777A (sh) |
NO (1) | NO20034538D0 (sh) |
PL (1) | PL367480A1 (sh) |
SK (1) | SK14612003A3 (sh) |
UA (1) | UA82828C2 (sh) |
WO (1) | WO2002087566A1 (sh) |
YU (1) | YU85303A (sh) |
ZA (1) | ZA200307102B (sh) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
MXPA03008777A (es) * | 2001-05-01 | 2004-02-12 | Lundbeck & Co As H | El uso de escitalopram enantiomericamente puro. |
WO2004056791A1 (en) * | 2002-12-23 | 2004-07-08 | H. Lundbeck A/S | Escitalopram hydrobromide and a method for the preparation thereof |
US20050037983A1 (en) * | 2003-03-11 | 2005-02-17 | Timothy Dinan | Compositions and methods for the treatment of depression and other affective disorders |
AR047553A1 (es) * | 2003-07-04 | 2006-01-25 | Lundbeck & Co As H | La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina |
PL1691811T3 (pl) * | 2003-12-11 | 2014-12-31 | Sunovion Pharmaceuticals Inc | Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji |
US20050196453A1 (en) | 2004-03-05 | 2005-09-08 | H. Lundbeck A/S | Crystalline composition containing escitalopram |
NZ549100A (en) * | 2004-03-05 | 2010-02-26 | Lundbeck & Co As H | Crystalline composition containing escitalopram oxalate |
TWI347942B (en) * | 2005-06-22 | 2011-09-01 | Lundbeck & Co As H | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
AU2006304889A1 (en) * | 2005-10-14 | 2007-04-26 | H. Lundbeck A/S | Stable pharmaceutical formulations containing escitalopram and bupropion |
AU2006308635A1 (en) * | 2005-10-14 | 2007-05-10 | H. Lundbeck A/S | Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion |
US20070134322A1 (en) * | 2005-12-14 | 2007-06-14 | Forest Laboratories, Inc. | Modified and pulsatile release pharmaceutical formulations of escitalopram |
CN100353939C (zh) * | 2006-01-05 | 2007-12-12 | 昆明积大制药有限公司 | 含西酞普兰和环糊精的抗抑郁口服药用组合物 |
US20070259952A1 (en) * | 2006-05-02 | 2007-11-08 | H. Lundbeck A/S | Uses of escitalopram |
TW200812993A (en) * | 2006-05-02 | 2008-03-16 | Lundbeck & Co As H | New uses of escitalopram |
CA2672925A1 (en) * | 2006-10-20 | 2008-04-24 | Ratiopharm Gmbh | Escitalopram and solid pharmaceutical composition comprising the same |
EP2078524B1 (en) * | 2006-10-27 | 2016-08-31 | Hisamitsu Pharmaceutical Co., Inc. | Adhesive skin patch |
EP2017271A1 (en) | 2007-07-06 | 2009-01-21 | Aurobindo Pharma Limited | Process for the preparation of escitalopram |
JP5460594B2 (ja) * | 2007-08-03 | 2014-04-02 | リチュテル・ゲデオン・ヴェジェーセティ・ジャール・ニュイルヴァーノシャン・ミューコェデー・レースヴェーニュタールシャシャーグ | ドーパミン受容体リガンドを含有する医薬組成物およびドーパミン受容体リガンドを用いる処置方法 |
CA2713598C (en) * | 2008-01-31 | 2016-07-05 | Takeda Pharmaceutical Company Limited | Prophylactic or therapeutic agent for attention deficit/hyperactivity disorder |
ITMI20080768A1 (it) * | 2008-04-24 | 2009-10-25 | Abiogen Pharma Spa | Procedimento per la preparazione di un composto in forma cristallina di 3-benzil-2-metil-2,3,3a,4,5,6,7,7a-ottaidro-benzo[d]isossazol-4-one |
WO2010098230A1 (ja) * | 2009-02-27 | 2010-09-02 | 久光製薬株式会社 | 経皮投与製剤 |
US20180071269A1 (en) | 2015-08-12 | 2018-03-15 | Tianxin Wang | Therapeutical methods, formulations and nutraceutical formulations |
CA2982898C (en) * | 2015-05-13 | 2023-08-29 | A. Carlsson Research Ab | Combination of dopamine stabilizing agent and an anti-depressive agent to treat a disorder characterized by debilitating fatigue |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1143702A (sh) * | 1965-03-18 | |||
US4079135A (en) * | 1973-12-13 | 1978-03-14 | Imperial Chemical Industries Limited | Morpholine derivatives as antidepressants |
GB1526331A (en) * | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
GB8419963D0 (en) * | 1984-08-06 | 1984-09-12 | Lundbeck & Co As H | Intermediate compound and method |
GB8607313D0 (en) * | 1986-03-25 | 1986-04-30 | Ici Plc | Pharmaceutical compositions |
GB8814057D0 (en) * | 1988-06-14 | 1988-07-20 | Lundbeck & Co As H | New enantiomers & their isolation |
US4902710A (en) * | 1988-12-14 | 1990-02-20 | Eli Lilly And Company | Serotonin and norepinephrine uptake inhibitors |
US5114976A (en) * | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
US4962128A (en) * | 1989-11-02 | 1990-10-09 | Pfizer Inc. | Method of treating anxiety-related disorders using sertraline |
US5296507A (en) * | 1990-09-06 | 1994-03-22 | H.Lundbeck A/S | Treatment of cerbrovascular disorders |
US5708035A (en) * | 1991-02-04 | 1998-01-13 | Sepracor Inc. | Methods of use and compositions of R(-) fluoxetine |
EP0714663A3 (en) * | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentiation of drug responses by serotonin 1A receptor antagonists |
US5627196A (en) * | 1995-01-17 | 1997-05-06 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
US5554383A (en) * | 1995-04-06 | 1996-09-10 | Trustees Of Tufts College | Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression |
SE9501567D0 (sv) * | 1995-04-27 | 1995-04-27 | Astra Ab | A new combination |
US5846982A (en) * | 1996-06-14 | 1998-12-08 | Eli Lilly And Company | Inhibition of serotonin reuptake |
US5747494A (en) * | 1996-06-28 | 1998-05-05 | U C B S.A. | Pharmaceutical compositions for the treatment of depressive disorders |
US5958429A (en) * | 1996-08-16 | 1999-09-28 | Eli Lilly And Company | Potentiation of serotonin response |
ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
US5776969A (en) * | 1997-02-27 | 1998-07-07 | Eli Lilly And Company | Treatment of sleep disorders |
US6069177A (en) * | 1997-07-08 | 2000-05-30 | The Hong Kong University Of Science And Technology | 3-Hydroxy-propanamine derived neuronal reuptake inhibitors |
SE9703375D0 (sv) * | 1997-09-18 | 1997-09-18 | Astra Ab | A new combination |
EP1042310B1 (en) * | 1997-11-11 | 2002-07-31 | H. Lundbeck A/S | Method for the preparation of citalopram |
AU4850199A (en) * | 1998-06-30 | 2000-01-17 | Eli Lilly And Company | Pyrrolidine and pyrroline derivatives having effects on serotonin related systems |
US6150376A (en) * | 1998-08-05 | 2000-11-21 | Georgetown University | Bi- and tri-cyclic aza compounds and their uses |
CN1129592C (zh) * | 1998-10-20 | 2003-12-03 | H·隆德贝克有限公司 | 制备西酞普兰的方法 |
EP1173431B2 (en) * | 1999-04-14 | 2009-08-26 | H. Lundbeck A/S | Method for the preparation of citalopram |
AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
US6333357B1 (en) * | 1999-11-05 | 2001-12-25 | Be Able, Llc | Behavior chemotherapy |
UA77650C2 (en) * | 1999-12-06 | 2007-01-15 | Lundbeck & Co As H | Use of serotonin reuptake inhibitor in combination with deramcyclane |
GB2357762B (en) * | 2000-03-13 | 2002-01-30 | Lundbeck & Co As H | Crystalline base of citalopram |
US6469064B2 (en) * | 2000-04-24 | 2002-10-22 | Aryx Therapeutics | Materials and methods for the treatment of depression |
MXPA03008777A (es) * | 2001-05-01 | 2004-02-12 | Lundbeck & Co As H | El uso de escitalopram enantiomericamente puro. |
-
2002
- 2002-05-01 MX MXPA03008777A patent/MXPA03008777A/es unknown
- 2002-05-01 ME MEP-59/08A patent/MEP5908A/xx unknown
- 2002-05-01 JP JP2002584912A patent/JP2004527551A/ja active Pending
- 2002-05-01 PL PL02367480A patent/PL367480A1/xx not_active Application Discontinuation
- 2002-05-01 YU YU85303A patent/YU85303A/sh unknown
- 2002-05-01 CN CNA028092309A patent/CN1509169A/zh active Pending
- 2002-05-01 UA UA2003098415A patent/UA82828C2/xx unknown
- 2002-05-01 EP EP02724141A patent/EP1385503A1/en not_active Withdrawn
- 2002-05-01 KR KR1020097027003A patent/KR20100012089A/ko not_active Application Discontinuation
- 2002-05-01 US US10/468,685 patent/US20040198809A1/en not_active Abandoned
- 2002-05-01 IL IL15803102A patent/IL158031A0/xx unknown
- 2002-05-01 BR BR0208283-7A patent/BR0208283A/pt not_active IP Right Cessation
- 2002-05-01 KR KR10-2003-7014286A patent/KR20040030609A/ko active Application Filing
- 2002-05-01 HU HU0400054A patent/HUP0400054A3/hu unknown
- 2002-05-01 SK SK1461-2003A patent/SK14612003A3/sk not_active Application Discontinuation
- 2002-05-01 CZ CZ20033267A patent/CZ20033267A3/cs unknown
- 2002-05-01 EA EA200301195A patent/EA200301195A1/ru unknown
- 2002-05-01 WO PCT/DK2002/000281 patent/WO2002087566A1/en active Application Filing
- 2002-05-01 CA CA002445843A patent/CA2445843A1/en not_active Abandoned
- 2002-05-02 AR ARP020101612A patent/AR033308A1/es unknown
-
2003
- 2003-08-20 US US10/644,588 patent/US20040192766A1/en not_active Abandoned
- 2003-08-20 US US10/644,579 patent/US20040192765A1/en not_active Abandoned
- 2003-08-20 US US10/644,577 patent/US20040198810A1/en not_active Abandoned
- 2003-08-20 US US10/644,587 patent/US20040198811A1/en not_active Abandoned
- 2003-08-20 US US10/644,576 patent/US20040192764A1/en not_active Abandoned
- 2003-09-11 ZA ZA200307102A patent/ZA200307102B/xx unknown
- 2003-09-15 IS IS6954A patent/IS6954A/is unknown
- 2003-09-16 HR HR20030744A patent/HRP20030744A2/xx not_active Application Discontinuation
- 2003-10-09 NO NO20034538A patent/NO20034538D0/no not_active Application Discontinuation
- 2003-11-24 BG BG108379A patent/BG108379A/bg unknown
-
2007
- 2007-09-12 US US11/853,949 patent/US20080004338A1/en not_active Abandoned
-
2008
- 2008-03-21 AT AT0017508U patent/AT10974U1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US20040198809A1 (en) | 2004-10-07 |
UA82828C2 (en) | 2008-05-26 |
SK14612003A3 (sk) | 2004-04-06 |
AR033308A1 (es) | 2003-12-10 |
HRP20030744A2 (en) | 2005-06-30 |
US20040198810A1 (en) | 2004-10-07 |
ZA200307102B (en) | 2004-09-13 |
US20040198811A1 (en) | 2004-10-07 |
KR20040030609A (ko) | 2004-04-09 |
MXPA03008777A (es) | 2004-02-12 |
CN1509169A (zh) | 2004-06-30 |
EP1385503A1 (en) | 2004-02-04 |
US20040192766A1 (en) | 2004-09-30 |
EA200301195A1 (ru) | 2004-04-29 |
JP2004527551A (ja) | 2004-09-09 |
PL367480A1 (en) | 2005-02-21 |
CA2445843A1 (en) | 2002-11-07 |
WO2002087566A1 (en) | 2002-11-07 |
US20040192765A1 (en) | 2004-09-30 |
US20080004338A1 (en) | 2008-01-03 |
AT10974U1 (de) | 2010-02-15 |
HUP0400054A2 (hu) | 2004-04-28 |
HUP0400054A3 (en) | 2007-03-28 |
CZ20033267A3 (en) | 2004-06-16 |
MEP5908A (xx) | 2010-02-10 |
NO20034538L (no) | 2003-10-09 |
US20040192764A1 (en) | 2004-09-30 |
BG108379A (bg) | 2004-11-30 |
IS6954A (is) | 2003-09-15 |
KR20100012089A (ko) | 2010-02-05 |
BR0208283A (pt) | 2004-03-09 |
IL158031A0 (en) | 2004-03-28 |
NO20034538D0 (no) | 2003-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA82828C2 (en) | The use of enantiomeric pure escitalopram for treatment of depression | |
NO20100333L (no) | Behandling av nevrotiske forstyrrelser | |
WO2006054057A3 (en) | New use for cannabinoid | |
TR199901172T2 (xx) | Yeni ikame edilmi� pirazol t�revleri. | |
IL158590A0 (en) | Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes | |
MXPA03006771A (es) | Anticuerpos modificados y metodos de uso. | |
MXPA03011515A (es) | Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos. | |
DE69428791D1 (de) | Verwendung vonModafinil zur Behandlung von Atemstillstand im Schlaf und zentral erregten Atembeschwerden | |
DK1163224T3 (da) | N-[2-hydroxy-3-(1-piperiinyl)propoxy]pyridin-1-oxid-3-carboximidoylchlorid og dets anvendelse i behandlingen af insulinresistens | |
MXPA05004621A (es) | Derivados de anilinopirazol utiles en el tratamiento de la diabetes. | |
ATE450622T1 (de) | Gene und proteine für verhinderung, vorhersage, prognose und therapie der herzgefäss-krankheit | |
WO2002081745A3 (en) | Genes involved in osteogenesis, and methods of use | |
JP2006514952A5 (sh) | ||
ATE199829T1 (de) | Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon | |
WO2003039468A3 (en) | Antimnemonic therapy for hypermemory syndromes | |
NO20061167L (no) | Kombinasjonen av en serotonin-reopptaksinhibitor og en glysintransporter type 1-inhibitor for behandling av depresjon | |
ATE408602T1 (de) | Monohyroxycarbamezepin zur verwendung bei der herstellung eines medikaments zur behandlung von affektiver psychose, aufmerksamkeits störungen und neuropathischen schmerzen | |
MY136683A (en) | Kappa opoid agonist for the treatment of irritable bladder | |
MXPA04010816A (es) | Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares. | |
DE60034110D1 (de) | Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien | |
DE60215219D1 (de) | Verwendung von darifenacin zur behandlung des harndrangs | |
WO2005056056A3 (en) | The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist | |
WO2006041838A3 (en) | Heparinoid compositions for treatment and prevention of dementia | |
ATE288263T1 (de) | Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis) | |
DE60224078D1 (de) | Verwendung von Mirtazapin zur Verbesserung der Behandlung von Menschen mit starken Depressionen, welche Träger des Gens für Apolipoprotein E4 sind. |